Exemestane

Generic Name: Exemestane

Brand Names: Aromasin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄O_₂

CAS Number: 107868-30-4

Unique Ingredient Identifier: NY22HMQ4BX

Background: Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Indication: For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Associated Conditions: Stage I Breast Cancer, Refractory, advanced Breast cancer

Associated Therapies: -

Clinical Trials

Exemestane in Post-Menopausal Women With NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Exemestane

First Posted Date: 2016-01-28

Last Posted Date: 2023-05-31

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 6

Registration Number: NCT02666105

Locations: 🇺🇸
Essentia Health Hibbing, Hibbing, Minnesota, United States
🇺🇸
Mayo Clinic Health System, Mankato, Minnesota, United States
🇺🇸
Essentia Health Park Rapids, Park Rapids, Minnesota, United States

and more 14 locations

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor Negative
HER2/Neu Negative
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma
Estrogen Receptor Positive
Progesterone Receptor Negative
Progesterone Receptor Positive

Interventions: Drug: Doxorubicin Hydrochloride
Drug: Anastrozole
Drug: Exemestane
Other: Laboratory Biomarker Analysis
Drug: Letrozole
Biological: Pembrolizumab

First Posted Date: 2016-01-07

Last Posted Date: 2024-03-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 30

Registration Number: NCT02648477

Locations: 🇺🇸
City of Hope Corona, Corona, California, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States

and more 3 locations

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: KHK2375
Drug: Exemestane

First Posted Date: 2015-12-08

Last Posted Date: 2022-06-21

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 15

Registration Number: NCT02623751

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Phase 2

Completed

Conditions: Stage 0 Breast Cancer AJCC v6 and v7
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage I Breast Cancer AJCC v7
Stage IIB Breast Cancer AJCC v6 and v7

Interventions: Drug: Exemestane
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Placebo Administration
Procedure: Therapeutic Conventional Surgery
Other: Questionnaire Administration

First Posted Date: 2015-11-06

Last Posted Date: 2023-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 180

Registration Number: NCT02598557

Locations: 🇮🇹
European Institute of Oncology, Milano, Italy
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇮🇹
Galliera Hospital, Genoa, Italy

and more 2 locations

A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Palbociclib
Drug: Exemestane
Drug: Leuprolide Acetate

First Posted Date: 2015-10-30

Last Posted Date: 2019-04-08

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 182

Registration Number: NCT02592746

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Palbociclib
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Fulvestrant

First Posted Date: 2015-09-15

Last Posted Date: 2017-08-01

Lead Sponsor: Fondazione Sandro Pitigliani

Target Recruit Count: 115

Registration Number: NCT02549430

Locations: 🇮🇹
Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy
🇮🇹
Istituto Europeo Oncologia, Milano, Italy
🇮🇹
Ospedale Antonio Perrino, Brindisi, Italy

and more 3 locations

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Chidamide
Drug: placebo
Drug: exemestane

First Posted Date: 2015-06-26

Last Posted Date: 2022-01-12

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 365

Registration Number: NCT02482753

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Jiangsu, China

and more 19 locations

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Phase 2

Recruiting

Conditions: Breast Cancer
Cancer of Breast
Breast Neoplasms
Cancer of the Breast

Interventions: Behavioral: FACT-B
Drug: Goserelin
Drug: Anastrozole
Drug: Exemestane
Drug: Fulvestrant
Drug: Tamoxifen
Other: Archived tissue collection

First Posted Date: 2015-06-19

Last Posted Date: 2024-07-29

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 50

Registration Number: NCT02476786

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Breast Cancer, Sexuality and Black Cohosh

Phase 4

Conditions: Sexuality

Interventions: Behavioral: WHOQOL questionnaire
Behavioral: FSFI questionnaire
Behavioral: kupperman scale
Drug: Cimicifuga racemosa
Drug: tamoxifen
Drug: exemestane

First Posted Date: 2015-06-10

Last Posted Date: 2017-03-20

Lead Sponsor: Irmandade da Santa Casa de Misericordia de Sao Paulo

Target Recruit Count: 60

Registration Number: NCT02467686

Locations: 🇧🇷
Carolina Furtado Macruz, Sao Paulo, Brazil

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Phase 3

Conditions: Metastatic Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Locally Advanced Malignant Neoplasm

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Fulvestrant

First Posted Date: 2015-03-31

Last Posted Date: 2016-06-15

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 745

Registration Number: NCT02404051

Locations: 🇮🇹
Azienda Ospedaliera Policlinico di Bari, Bari, Italy
🇮🇹
A.O.R.N.A.S. Garibaldi Nesima di Catania, Catania, Italy
🇮🇹
Presidio Ospedaliero Antonio Perrino, Brindisi, Italy

and more 38 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy